PharmaTher targets new U.S. peptide pathway with 3D printed colon-release tablets
3D Printing Industry
AI SUMMARY
PharmaTher is developing 3D printed peptide tablets designed to release medication in the colon, leveraging a new U.S. compounding pathway. The company's first products use additive manufacturing technology to create specialized oral tablets of KPV and BPC-157.
FROM THE ARTICLE
PharmaTher Holdings is building a range of 3D printed peptide products for a new U.S. compounding pathway. The first two are oral tablets of KPV and BPC-157 designed to release their dose in the colon. It is timed to the U.S. Department of Health and Human Services (HHS) policy that lets qualified…
This story was originally published by 3D Printing Industry.
Read Full Story on 3D Printing IndustryRelated Stories
3D Printing & Prefab3DMakerpro’s Owl 3D Scanner Aims to Make LiDAR Scanning Affordable3D Printing Industry3D Printing & Prefab7,000 parts for a neutron machine: Freemelt wins ESS tungsten deal3D Printing IndustryAI & Machine LearningAI Model Designs 3D Printed Bone Scaffolds in 12 Seconds3D Printing Industry3D Printing & PrefabFarsoon Files $479M Raise for New Manufacturing Services Expansion3D Printing Industry